RT Journal Article
SR Electronic
T1 MPN Transformation Is Characterized By Heterogeneous Shifts In Lineage Character Resulting In Both HSC-Like And More Differentiated Lineage Signatures
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.04.16.24305909
DO 10.1101/2024.04.16.24305909
A1 Menghrajani, Kamal
A1 Dilip, Deepika
A1 Farnoud, Noushin
A1 Famulare, Chris
A1 McGovern, Erin
A1 Sirenko, Maria
A1 Mascarenhas, John
A1 Kosiorek, Heidi
A1 Hoffman, Ronald
A1 Levine, Ross
A1 Koche, Richard
A1 Rampal, Raajit
A1 Glass, Jacob
YR 2024
UL http://medrxiv.org/content/early/2024/04/19/2024.04.16.24305909.abstract
AB Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs) have a propensity to transform to an accelerated or blast phase (MPN-AP/BP). The resulting disease has clinically similar manifestations to Acute Myeloid Leukemia (AML) but worse clinical outcomes. Here we present the first comprehensive description of the transcriptomic characteristics of MPN-AP/BP. Our analysis incorporates data from 261 patients of the BeatAML cohort and 56 MPN-AP/BP patients, 11 of whom had paired samples from before and after transformation. We establish that transformed MPN is a transcriptionally distinct entity from de novo AML and chronic phase MPNs. Genomic pathways traditionally associated with MPN pathogenesis, such as IL2/STAT5 signaling, IL6/JAK/STAT3 signaling, and NUP98/HOXA9 fusions, were enriched in chronic-phase MPNs but are absent in transformed disease, suggesting JAK2 directed therapy may be less effective in this disease phase. We also discovered that gene expression signatures associated with doxorubicin resistance are highly enriched in transformed MPNs, which may explain the lack of efficacy of standard AML therapies. In addition, we identify that lineage composition at the time of transformation may define distinct subsets of MPN-AP/BP patients, which may assist in the future development of novel treatment strategies.Key Points- Accelerated- and blast-phase transformed MPNs are a transcriptionally entities which are distinct from de novo AML.- Transformed MPNs may be characterized by their lineage characteristics, which can drive clinical behavior and account for their inferior overall survival- Gene expression signatures associated with doxorubicin resistance were highly enriched in transformed MPNs, which may explain the lack of effectiveness of anthracycline-based therapiesCompeting Interest StatementThe authors have declared no competing interest.Funding StatementNIH 5K08CA230172 Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB of Memorial Sloan Kettering Cancer Center gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE210253